Rheumatoid Arthritis

You have full text access to this OnlineOpen article

Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti–tumor necrosis factor α therapy: Is there a need for more comprehensive screening procedures?

  1. Carlotta Nannini1,*,
  2. Fabrizio Cantini1,
  3. Laura Niccoli1,
  4. Emanuele CassarÀ1,
  5. Carlo Salvarani2,
  6. Ignazio Olivieri3,
  7. Edward V. Lally4

Article first published online: 28 MAY 2009

DOI: 10.1002/art.24506

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 61, Issue 6, pages 801–812, 15 June 2009

Additional Information

How to Cite

Nannini, C., Cantini, F., Niccoli, L., CassarÀ, E., Salvarani, C., Olivieri, I. and Lally, E. V. (2009), Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti–tumor necrosis factor α therapy: Is there a need for more comprehensive screening procedures?. Arthritis & Rheumatism, 61: 801–812. doi: 10.1002/art.24506

Author Information

  1. 1

    Hospital Misericordia e Dolce, Prato, Italy

  2. 2

    Hospital S. Maria Nuova, Reggio Emilia, Italy

  3. 3

    Hospital S. Carlo, Potenza, and Hospital Madonna delle Grazie, Matera, Italy

  4. 4

    Rhode Island Hospital, Providence

*2nd Division of Medicine, Rheumatology Unit, Hospital Misericordia e Dolce, Prato, Piazza Ospedale, 1-59100, Prato, Italy

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 28 MAY 2009
  3. Manuscript Accepted: 19 FEB 2009
  4. Manuscript Received: 20 NOV 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (109K)

REFERENCES

  • 1
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63.
    Direct Link:
  • 2
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932–9.
  • 3
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, and the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
  • 4
    St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432–43.
    Direct Link:
  • 5
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 27–35.
    Direct Link:
  • 6
    Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al, for the qqSTART Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54: 1075–86.
    Direct Link:
  • 7
    Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 2006; 3: 37–44.
  • 8
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Trial (IMPACT). Arthritis Rheum 2005; 52: 1227–36.
    Direct Link:
  • 9
    Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al, and the IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150–7.
  • 10
    Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755–65.
    Direct Link:
  • 11
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187–93.
  • 12
    Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582–91.
    Direct Link:
  • 13
    Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'Connor P, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005; 64: 1568–75.
  • 14
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9.
  • 15
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478–86.
  • 16
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published errata appear in N Engl J Med 2001;344:240 and 2001;344:76]. N Engl J Med 2000; 343: 1586–93.
  • 17
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675–81.
  • 18
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 353–63.
    Direct Link:
  • 19
    Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al, for the TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54: 1063–74.
    Direct Link:
  • 20
    Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al, for the Etanercept European Investigators Network (Etanercept Study 309 Investigators). Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006; 65: 1357–62.
  • 21
    Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford) 2007; 46: 1122–5.
  • 22
    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–90.
  • 23
    Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264–72.
    Direct Link:
  • 24
    Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 1349–56.
  • 25
    Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667–75.
    Direct Link:
  • 26
    Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al, for the Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230–6.
    Direct Link:
  • 27
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594–600.
  • 28
    Van der Heijde D, da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 1572–7.
  • 29
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563–71.
  • 30
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35–45.
    Direct Link:
  • 31
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400–11.
    Direct Link:
  • 32
    Van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508–16.
  • 33
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37.
    Direct Link:
  • 34
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279–89.
    Direct Link:
  • 35
    Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al, for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136–46.
    Direct Link:
  • 36
    Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 2008; 372: 375–82.
  • 37
    Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2004; 43 Suppl 3: 17–23.
  • 38
    Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol 2006; 33: 1422–30.
  • 39
    Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56: 476–88.
    Direct Link:
  • 40
    Manadan AM, James N, Block JA. New therapeutic approaches for spondylarthritis. Curr Opin Rheumatol 2007; 19: 259–64.
  • 41
    Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13: 135–41.
  • 42
    Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005; 16: 35–53.
  • 43
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275–85.
  • 44
    Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421–6.
  • 45
    Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414–20.
  • 46
    Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (Humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889–94.
  • 47
    Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, et al. Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2757–64.
    Direct Link:
  • 48
    Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group Register. Ann Rheum Dis 2008; 67: 364–92.
  • 49
    Wolfe F, Michaud K. The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433–9.
    Direct Link:
  • 50
    Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699–703.
  • 51
    Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Post-marketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189–94.
  • 52
    Salvarani C, Cantini F, Olivieri I, Macchioni P, Padula A, Niccoli L, et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003; 49: 541–5.
    Direct Link:
  • 53
    Cantini F, Niccoli L, Benucci M, Chindamo D, Nannini C, Olivieri I, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four–week study. Arthritis Rheum 2006; 55: 812–6.
    Direct Link:
  • 54
    Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732–9.
  • 55
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 56
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8.
  • 57
    Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55–78.
  • 58
    Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817–24.
  • 59
    Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, et al, for the ACS Prostate Cancer Advisory Committee, the ACS Colorectal Cancer Advisory Committee, and the ACS Endometrial Cancer Advisory Committee. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001. Testing for early lung cancer detection [published erratum appears in CA Cancer J Clin 2001;51:150]. CA Cancer J Clin 2001; 51: 38–75.
    Direct Link:
  • 60
    Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327–32.
    Direct Link:
  • 61
    Martinez-Ares D, Martin-Granizo Barrenechea I, Souto-Ruzo J, Yanez Lopez J, Pallares Peral Al, Vazquez-Iglesias JL. The value of abdominal ultrasound in the diagnosis of colon cancer. Rev Esp Enferm Dig 2005; 97: 877–86.
  • 62
    Martinez-Ares D, Alonso Aguirre PA, Yanez Lopez J, Martin-Granizo Barrenechea I, Martinez Cadilla J, Rodriguez Martinez D, et al. Sensitivity of ultrasonography for gastric cancer diagnosis in symptomatic patients. Dig Dis Sci 2008. E-pub ahead of print.
  • 63
    Toyoda Y, Nakayama Y, Kusunoki Y, Iso H, Suzuki T. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. Br J Cancer 2008; 98: 1602–7.
  • 64
    Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancies: analysis from a large US observational study. Arthritis Rheum 2007; 56: 2886–95.
    Direct Link:
  • 65
    Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350–5.
  • 66
    Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 1998; 52: 239–59.
  • 67
    Rosenthal AN, Jacobs IJ. The role of CA 125 in screening for ovarian cancer. Int J Biol Markers 1998; 13: 216–20.
  • 68
    Morra E. The biological markers of non-Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy. Int J Biol Markers 1999; 14: 149–53.
  • 69
    Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008; 100: 1432–8.
  • 70
    Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354: 99–105.
  • 71
    Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000; 109: 201–6.
  • 72
    Kahi CJ, Imperiale TF. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med 2004; 117: 837–41.
  • 73
    Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–7.
  • 74
    Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328–32.
View Full Article (HTML) Get PDF (109K)